PhD | Director Therapeutic Innovation and BaseLaunch
Tel. +41 61 295 50 17stephan. emmerth@baselarea. swiss
Novartis currently has 26 product candidates that have the potential to be blockbusters for the Basel pharmaceutical company. A total of 60 major submissions are planned between 2019 and 2021.
Of the 26 most promising product candidates, 13 are already in the clinical development stage, Novartis reported in a press release. These 13 therapies are in the progressing cell, gene and radioligand platforms, as are the nine other product candidates that are expected to enter the clinic next year.
In particular, Novartis mentions the gene therapy AVXS101, which has been developed to benefit in spinal muscular atrophy Type 1. Regulatory approvals are anticipated for this drug in the USA, Europe and Japan in the first half of 2019. Mayzen is expected to launch in the first quarter of 2019, as the “first and only” drug proven to delay progression for typical patients living with secondary progressive multiple sclerosis (SPMS), Novartis explained. In addition, product candidates for the treatment of neovascular age-related macular degeneration, asthma, sickle cell anaemia and lung cancer are all in advanced stages of development.
The investor update provided by Novartis in London not only offered an overview of research activities but also focused on existing drugs. The Basel-based pharmaceutical company reported that it is building out the data profiles for the already successful drugs Cosentyx, Entresto and Gilenya in order to gain approval for further indications.